Shoulder Innovations UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Alrighty. Amazing. Well, thank you so much, and welcome everybody. It's Patrick Wood on the UBS MedTech team. Thank you so much for joining, and big thank you to Rob.
Thanks for having us. CEO of Shoulder Innovations for joining.
Thanks so much for joining.
Our pleasure. My pleasure. Yeah.
I think maybe just want to make sure that we can level set everybody, because SI is a newer story within orthopedics in the public markets. What might be helpful would be just a brief big picture of how you fit into the shoulder arthroplasty landscape, and then we can take from there.
Yeah, sure. I think the place to really start is to think about a new way to imagine the shoulder space, which is what I characterize as the shoulder surgical care market. Our first landing point there is shoulder arthroplasty. The vast majority of both soft tissue and hard tissue, so arthroplasty procedures in this space are performed by shoulder specialists. There is no company out there that has declared themselves focused on the shoulder specialist besides Shoulder Innovations. Our first landing point, of course, into that shoulder surgical care space is the arthroplasty market. I think about those two, soft tissue, hard tissue, combines probably around a $5 billion market or a TAM in the United States. Of course, we're focused on shoulder arthroplasty alone today, and a vast majority of our customers are those high-volume shoulder specialists.
Interestingly, likely in most cases, less than half of the practice of those specialists is indeed shoulder arthroplasty. That's kind of overall the market and the way we think about the market. Of course, that implies over time as we've built a commercial organization that's effective at calling on that high-volume shoulder specialist, arthroplasty will be one part of our business relationship with them as we think about soft tissue procedures, though.
Definitely want to dig into that.
Sure a little bit more.
There are some hints there. But maybe just to start with the shoulder market overall, it is seemingly excellent growth. Maybe for those people who are less familiar, growing dramatically faster than hip and knee and some of the other procedures out there.
Very much so. Could you help paint the picture for people of why?
What is driving patients to now move to shoulder replacement?
Yeah, I think there are two significant dynamics there. One is just, as must be the case in any high-growth market, there must be some sort of supply-demand imbalance there. Indeed, that is indeed the case. When you look at the number of visits to a clinician for knee pain versus shoulder pain, they are about the same numbers annually, but there are many fewer shoulder surgical procedures performed than knee procedures, and you have to ask yourself the question why. In reality, there are two substantial issues you are dealing with in the shoulder. You are dealing with arthritis, and you are dealing with rotator cuff deficiency. Until about 20 years ago, we did not have an effective way to deal with both of those when you had ailed from both arthritis and rotator cuff deficiency. With the advent of reverse shoulder arthroplasty, that now has been largely solved.
Prior to reverse shoulder arthroplasty, which has been with us about 20 years in the U.S., and having anatomic shoulder arthroplasty alone, it was really insufficient to treat those patients. Fast-forward to today, about 70% of unit volume is reverse shoulder arthroplasty. You've had this massive population of patients that needed reverse shoulder arthroplasty, did not have that available to them, and so we've been kind of growing into that marketplace. We've just seen a bit of an asymptote in terms of that balance between reverse shoulder arthroplasty and anatomic of about 70/30 that's arrived here over the last, call it three, four, five years. Relatively recently, implying that we have some recency that the market has matured, and now we have this backlog of patients to work our way through.
What might be helpful, just to make sure everyone knows where they're at, explaining the reverse and anatomic switch-up and why one is helpful for the rotator cuff deficiency.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
